Cargando…

The association between gut microbiome affecting concomitant medication and the effectiveness of immunotherapy in patients with stage IV NSCLC

Several observational studies suggested that gut microbiome-affecting-medication impairs the effectiveness of immunotherapy in patients with metastatic non-small-cell lung cancer (NSCLC). We postulated that if the effectiveness of immunotherapy is affected by drug-related changes of the microbiome,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Verschueren, M. V., van der Welle, C. M. Cramer -, Tonn, M., Schramel, F. M. N. H., Peters, B. J. M., van de Garde, E. M. W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640057/ https://www.ncbi.nlm.nih.gov/pubmed/34857829 http://dx.doi.org/10.1038/s41598-021-02598-0

Ejemplares similares

Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands
por: Cramer-van der Welle, Christine M., et al.
Publicado: (2021)

Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from first-line immunotherapy in NSCLC
por: Ismail, R. K., et al.
Publicado: (2023)

Correction: Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from second-line immunotherapy in NSCLC
por: Ismail, R. K., et al.
Publicado: (2023)

Trends in Drug Costs and Overall Survival in Patients with Metastatic Non-small Cell Lung Cancer in The Netherlands Diagnosed from 2008 Through 2014
por: Cramer-van der Welle, Christine M., et al.
Publicado: (2020)

Systematic evaluation of the efficacy–effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer
por: Cramer-van der Welle, Christine M., et al.
Publicado: (2018)

Real‐world treatment patterns and outcomes of patients with extensive disease small cell lung cancer
por: Cramer‐van der Welle, Christine M., et al.
Publicado: (2020)

Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC)
por: Assi, Hazem I., et al.
Publicado: (2023)

‘Care for Outcomes’: systematic development of a set of outcome indicators to improve patient-relevant outcomes for patients with lung cancer
por: Cramer-van der Welle, Christine M, et al.
Publicado: (2021)

Prognostic Implication of KRAS G12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands
por: Noordhof, Anneloes L., et al.
Publicado: (2023)

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
por: Fitzpatrick, Orla, et al.
Publicado: (2021)

The Impact of the Availability of Immunotherapy on Patterns of Care in Stage III NSCLC: A Dutch Multicenter Analysis
por: Ronden, Merle I., et al.
Publicado: (2021)

Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands
por: Mfumbilwa, Zakile A., et al.
Publicado: (2023)

Gut Microbiome and the Response to Immunotherapy in Cancer
por: Stancu, Andreea Lucia
Publicado: (2018)

Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept
por: Berghmans, Thierry, et al.
Publicado: (2020)

Pretreatment radiomic biomarker for immunotherapy responder prediction in stage IB–IV NSCLC (LCDigital-IO Study): a multicenter retrospective study
por: Wu, Shaowei, et al.
Publicado: (2023)

Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma
por: Zheng, Yi, et al.
Publicado: (2019)

Tumor Primary Location May Affect Metastasis Pattern for Patients with Stage IV NSCLC: A Population-Based Study
por: Shan, Qinge, et al.
Publicado: (2020)

Role of gut microbiome on immunotherapy efficacy in melanoma
por: Bibbò, Stefano, et al.
Publicado: (2021)

Implication of gut microbiome in immunotherapy for colorectal cancer
por: Koustas, Evangelos, et al.
Publicado: (2022)

Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations
por: Ninomiya, Kiichiro, et al.
Publicado: (2020)

180P Incidence of brain metastases (BM) in newly diagnosed stage IV NSCLC during COVID-19
por: Cui, W., et al.
Publicado: (2021)

The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?
por: Oh, Byeongsang, et al.
Publicado: (2021)

Yogurt Benefits Bone Mineralization in Ovariectomized Rats with Concomitant Modulation of the Gut Microbiome
por: He, Weiwei, et al.
Publicado: (2022)

Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report
por: Guisier, F., et al.
Publicado: (2020)

Proton pump inhibitors affect the gut microbiome
por: Imhann, Floris, et al.
Publicado: (2016)

Gut microbiome and stages of diabetes in middle-aged adults: CARDIA microbiome study
por: Hu, Yi-Han, et al.
Publicado: (2023)

Maternal vaginal microbiome composition does not affect development of the infant gut microbiome in early life
por: Dos Santos, Scott J., et al.
Publicado: (2023)

Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome
por: Temraz, Sally, et al.
Publicado: (2021)

Gut microbiome homeostasis and the future of probiotics in cancer immunotherapy
por: Singh, Ankita, et al.
Publicado: (2023)

Dietary Patterns Affect the Gut Microbiome—The Link to Risk of Cardiometabolic Diseases
por: Tindall, Alyssa M, et al.
Publicado: (2018)

The Predictive Value of Peripheral Immune Cell Counts for the Presence of Brain Metastases in Stage IV Non-Small-Cell Lung Cancer (NSCLC)
por: Abuelbeh, I, et al.
Publicado: (2022)

Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study
por: Pujol, Jean-Louis, et al.
Publicado: (2021)

The Landscape of Immunotherapy Resistance in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2022)

Gut microbiome alterations in patients with stage 4 hepatitis C
por: Aly, AbdelRahman Mahmoud, et al.
Publicado: (2016)

Cryotherapy for nodal metastasis in NSCLC with acquired resistance to immunotherapy
por: Adam, Lucas C., et al.
Publicado: (2018)

Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08)
por: Curioni-Fontecedro, Alessandra, et al.
Publicado: (2019)

Gut Microbiome: A Promising Biomarker for Immunotherapy in Colorectal Cancer
por: Temraz, Sally, et al.
Publicado: (2019)

The role of the sex hormone-gut microbiome axis in tumor immunotherapy
por: Wang, Luoyang, et al.
Publicado: (2023)

The Gut Microbiome, Microsatellite Status and the Response to Immunotherapy in Colorectal Cancer
por: Sillo, Toritseju O., et al.
Publicado: (2023)

Early life environment affects behavior, welfare, gut microbiome composition, and diversity in broiler chickens
por: de Jong, Ingrid C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mjolpg3adv8qiql65hhm7bj40t